- Email: [email protected]
Selected Clinical Trials in Non-Small-Cell Lung Cancer
clinical trials list Selected Clinical Trials in Non–Small-Cell Lung Cancer Early-Stage Disease Title: A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 CM) Peripheral Non–Small-Cell Lung Cancer – (NCT00499330) Sponsor: Cancer and Leukemia Group B Accrual Goal: 1297 Contact Information: Nasser Altorki, MD, Protocol chair; Ph: 212-746-5156 Title: GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3 Positive Non–Small-Cell Lung Cancer – (NCT00480025) Sponsor: GlaxoSmithKline Accrual Goal: 2270 Contact Information: US GSK Clinical Trials Call Center; Ph: 877-379-3718 Title: A Phase III Randomized Trial of Adjuvant Chemotherapy with or Without Bevacizumab for Patients with Completely Resected Stage IB (> 4 cm)-IIIA Non–Small-Lung Cancer (NSCLC) – (NCT00324805) Sponsor: Eastern Cooperative Oncology Group Accrual Goal: 1500 Contact Information: Heather Wakelee, MD, Protocol chair; Ph: 650-723-9094; 800-756-9000 Title: RADIANT: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Single-Agent Tarceva® (Erlotinib) Following Complete Tumor Resection with or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non–Small-Cell Lung Carcinoma Who Have EGFR-Positive Tumors – (NCT00373425) Sponsor: OSI Pharmaceuticals Accrual Goal: 945 Contact Information: OSIP Medical Information; Ph: 800-572-1932 Title: A Randomized Phase III Trial of Adjuvant Therapy in Early Stage Non–Small-Cell Lung Cancer Evaluating the Potential Utility of a Genomic Prognostic Model to Identify Patients as Candidates for Adjuvant Chemotherapy – (NCT00863512) Sponsor: Cancer and Leukemia Group B Accrual Goal: 1525 Contact Information: David Harpole, MD, Protocol chair; Ph: 919-668-8413 Locally Advanced Disease Title: A Multi-Center Phase III Randomized, Double-Blind Placebo-Controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non–Small-Cell Lung Cancer (NSCLC) Subjects with Unresectable Stage III Disease – (NCT00409188) Sponsor: Merck KGaA Accrual Goal: 1322 Contact Information: Ph: 800-507-5284 Title: Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non–Small-Cell Lung Cancer Other Than Predominantly Squamous Cell Histology – (NCT00686959) Sponsor: Eli Lilly and Company Accrual Goal: 600 Contact Information: Ph: 877-285-4559 or 317-615-4559 Title: A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer – (NCT00533949) Sponsor: Radiation Therapy Oncology Group Accrual Goal: 500 Contact Information: Jeffrey Bradley, MD, Protocol chair; Ph: 314-362-8525 First-Line Metastatic Disease Title: Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer – (NCT00762034) Sponsor: Eli Lilly and Company Accrual Goal: 900 Contact Information: Ph: 877-CTLILLY (877-285-4559) or 317-615-4559
This article might include the discussion of investigational and/or unlabeled uses of drugs and/or devices that might not be approved by the FDA. Electronic forwarding or copying is a violation of US and international copyright laws. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1525-7304, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. www.copyright.com 978-750-8400.
Clinical Lung Cancer July 2009
|
257
Selected Clinical Trials in Non–Small-Cell Lung Cancer First-Line Metastatic Disease Title: Randomized, Open Label, Phase III Trial of CP-751,871 in Combination with Paclitaxel And Carboplatin Versus Paclitaxel and Carboplatin in Patients with Non–Small-Cell Lung Cancer – (NCT00596830) Sponsor: Pfizer Accrual Goal: 820 Contact Information: Pfizer Oncology Clinical Trial Information Service; Ph: 877-369-9753 Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404 in Combination with Paclitaxel and Carboplatin as First-Line Treatment for Locally Advanced or Metastatic (Stage IIIb/IV) Non–Small-Cell Lung Cancer (NSCLC) – (NCT00662597) Sponsor: Novartis Pharmaceuticals Accrual Goal: 1200 Contact Information: Novartis Pharmaceuticals; Ph: 800-340-6843 Title: A Randomized, Placebo-Controlled, Double-Blind Phase III Study of the Effect of First-Line Treatment with Intercalated Tarceva Versus Placebo in Combination with Gemcitabine/Platinum on Progression-Free Survival in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer – (NCT00883779) Sponsor: Hoffmann-La Roche Accrual Goal: 450 Contact Information: Ph: 973-235-5000; 800-526-6367 (for US only) Metastatic Pretreated Title: A Phase III Biomarker Validation Study of Second-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib – (NCT00738881) Sponsor: North Central Cancer Treatment Group (Multicenter) Accrual Goal: 1196 Contact Information: Alex Adjei, MD, PhD, Protocol chair; Ph: 716-845-4101; 800-685-6825; e-mail: [email protected] Title: A Phase III, Multi-Center, Placebo-Controlled Trial of Sorafenib (BAY 43-9006) in Patients with Relapsed or Refractory Advanced Predominantly Non Squamous Non–Small-Cell Lung Cancer (NSCLC) After 2 or 3 Previous Treatment Regimens – (NCT00863746) Sponsor: Bayer Accrual Goal: 850 Contact Information: Bayer Clinical Trials Contact; Ph: 888-842-2937; e-mail: [email protected] Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404 in Combination with Docetaxel in Second-Line Treatment of Patients with Locally Advanced or Metastatic (Stage IIIb/IV) Non–Small-Cell Lung Cancer (NSCLC) – (NCT00738387) Sponsor: Novartis Pharmaceuticals Accrual Goal: 900 Contact Information: Novartis Pharmaceuticals; Ph: 800-340-6843 Title: Randomized, Open Label, Phase 3 Trial of Erlotinib Alone or in Combination with Cp 751,871 in Patients with Advanced Non–Small-Cell Lung Cancer of Non Adenocarcinoma Histology – (NCT00673049) Sponsor: Pfizer Accrual Goal: 600 Contact Information: Pfizer Oncology Clinical Trial Information Service; Ph: 877-369-9753; e-mail: pfi[email protected] Brain Metastases Title: A Phase III Trial Comparing Whole-Brain Radiation And Stereotactic Radiosurgery Alone Versus With Temozolomide Or Erlotinib In Patients With Non-Small Cell Lung Cancer And 1-3 Brain Metastases – (NCT00096265) Sponsor: Radiation Therapy Oncology Group Accrual Goal: 381 Contact Information: Paul Sperduto, MD, Protocol chair; Ph: 952-442-6000; e-mail: [email protected] Title: A Randomized, Phase III, Open-Label Study of Oral Topotecan plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients with Brain Metastases From Non–Small-Cell Lung Cancer – (NCT00390806) Sponsor: GlaxoSmithKline Accrual Goal: 675 Contact Information: 877-379-3718 Proteomics Title: A Feasibility Study Investigating Translational Science in Chemotherapy-Naive Patients with Stage IIIb or IV Non–Small-Cell Lung Cancer (NSCLC) Treated with the EGFR-TKI, Erlotinib – (NCT00550537) Sponsor: Vanderbilt-Ingram Cancer Center Accrual Goal: 210 Contact Information: Clinical Trials Office, Vanderbilt-Ingram Cancer Center; Ph: 800-811-8480
258
|
Clinical Lung Cancer July 2009
This article might include the discussion of investigational and/or unlabeled uses of drugs and/or devices that might not be approved by the FDA. Electronic forwarding or copying is a violation of US and international copyright laws. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1525-7304, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. www.copyright.com 978-750-8400.
Clinical Lung Cancer July 2009
|
257
Selected Clinical Trials in Non–Small-Cell Lung Cancer First-Line Metastatic Disease Title: Randomized, Open Label, Phase III Trial of CP-751,871 in Combination with Paclitaxel And Carboplatin Versus Paclitaxel and Carboplatin in Patients with Non–Small-Cell Lung Cancer – (NCT00596830) Sponsor: Pfizer Accrual Goal: 820 Contact Information: Pfizer Oncology Clinical Trial Information Service; Ph: 877-369-9753 Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404 in Combination with Paclitaxel and Carboplatin as First-Line Treatment for Locally Advanced or Metastatic (Stage IIIb/IV) Non–Small-Cell Lung Cancer (NSCLC) – (NCT00662597) Sponsor: Novartis Pharmaceuticals Accrual Goal: 1200 Contact Information: Novartis Pharmaceuticals; Ph: 800-340-6843 Title: A Randomized, Placebo-Controlled, Double-Blind Phase III Study of the Effect of First-Line Treatment with Intercalated Tarceva Versus Placebo in Combination with Gemcitabine/Platinum on Progression-Free Survival in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer – (NCT00883779) Sponsor: Hoffmann-La Roche Accrual Goal: 450 Contact Information: Ph: 973-235-5000; 800-526-6367 (for US only) Metastatic Pretreated Title: A Phase III Biomarker Validation Study of Second-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib – (NCT00738881) Sponsor: North Central Cancer Treatment Group (Multicenter) Accrual Goal: 1196 Contact Information: Alex Adjei, MD, PhD, Protocol chair; Ph: 716-845-4101; 800-685-6825; e-mail: [email protected] Title: A Phase III, Multi-Center, Placebo-Controlled Trial of Sorafenib (BAY 43-9006) in Patients with Relapsed or Refractory Advanced Predominantly Non Squamous Non–Small-Cell Lung Cancer (NSCLC) After 2 or 3 Previous Treatment Regimens – (NCT00863746) Sponsor: Bayer Accrual Goal: 850 Contact Information: Bayer Clinical Trials Contact; Ph: 888-842-2937; e-mail: [email protected] Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404 in Combination with Docetaxel in Second-Line Treatment of Patients with Locally Advanced or Metastatic (Stage IIIb/IV) Non–Small-Cell Lung Cancer (NSCLC) – (NCT00738387) Sponsor: Novartis Pharmaceuticals Accrual Goal: 900 Contact Information: Novartis Pharmaceuticals; Ph: 800-340-6843 Title: Randomized, Open Label, Phase 3 Trial of Erlotinib Alone or in Combination with Cp 751,871 in Patients with Advanced Non–Small-Cell Lung Cancer of Non Adenocarcinoma Histology – (NCT00673049) Sponsor: Pfizer Accrual Goal: 600 Contact Information: Pfizer Oncology Clinical Trial Information Service; Ph: 877-369-9753; e-mail: pfi[email protected] Brain Metastases Title: A Phase III Trial Comparing Whole-Brain Radiation And Stereotactic Radiosurgery Alone Versus With Temozolomide Or Erlotinib In Patients With Non-Small Cell Lung Cancer And 1-3 Brain Metastases – (NCT00096265) Sponsor: Radiation Therapy Oncology Group Accrual Goal: 381 Contact Information: Paul Sperduto, MD, Protocol chair; Ph: 952-442-6000; e-mail: [email protected] Title: A Randomized, Phase III, Open-Label Study of Oral Topotecan plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients with Brain Metastases From Non–Small-Cell Lung Cancer – (NCT00390806) Sponsor: GlaxoSmithKline Accrual Goal: 675 Contact Information: 877-379-3718 Proteomics Title: A Feasibility Study Investigating Translational Science in Chemotherapy-Naive Patients with Stage IIIb or IV Non–Small-Cell Lung Cancer (NSCLC) Treated with the EGFR-TKI, Erlotinib – (NCT00550537) Sponsor: Vanderbilt-Ingram Cancer Center Accrual Goal: 210 Contact Information: Clinical Trials Office, Vanderbilt-Ingram Cancer Center; Ph: 800-811-8480
258
|
Clinical Lung Cancer July 2009